{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:31:57Z","timestamp":1783531917522,"version":"3.55.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,8]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>PD-L1 expression in neoplastic cells or stromal cells is associated with poor or good prognosis in ATLL, respectively. Distinction of expression pattern of PD-L1 might be important on the point of prognostic and therapeutic markers in ATLL.<\/jats:p>","DOI":"10.1182\/blood-2016-02-698936","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T03:23:57Z","timestamp":1468553037000},"page":"1374-1381","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":119,"title":["PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma"],"prefix":"10.1182","volume":"128","author":[{"given":"Hiroaki","family":"Miyoshi","sequence":"first","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kiyasu","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"},{"name":"Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Shimono","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sasebo City General Hospital, Sasebo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Seto","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111912154776300_B1","first-page":"281","article-title":"Adult T-cell leukemia\/lymphoma.","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Ohshima","year":"2008"},{"issue":"3","key":"2019111912154776300_B2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87).","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111912154776300_B3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A).","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br J Haematol"},{"issue":"20","key":"2019111912154776300_B4","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-14-0572","article-title":"Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research.","volume":"20","author":"Tsukasaki","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111912154776300_B5","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma.","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111912154776300_B6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/cas.12617","article-title":"Recent advances in the treatment of adult T-cell leukemia-lymphomas.","volume":"106","author":"Utsunomiya","year":"2015","journal-title":"Cancer Sci"},{"issue":"24","key":"2019111912154776300_B7","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL.","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"27","key":"2019111912154776300_B8","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes.","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"35","key":"2019111912154776300_B9","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma.","volume":"29","author":"Hodson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111912154776300_B10","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1038\/bcj.2013.57","article-title":"Association between decreasing trend in the mortality of adult T-cell leukemia\/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT).","volume":"3","author":"Chihara","year":"2013","journal-title":"Blood Cancer J"},{"issue":"8","key":"2019111912154776300_B11","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study.","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111912154776300_B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coi.2007.04.012","article-title":"PD-1 and its ligands in T-cell immunity.","volume":"19","author":"Keir","year":"2007","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"2019111912154776300_B13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity.","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol"},{"issue":"8","key":"2019111912154776300_B14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"6","key":"2019111912154776300_B15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment.","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"2 Pt 2","key":"2019111912154776300_B16","doi-asserted-by":"crossref","first-page":"709s","DOI":"10.1158\/1078-0432.CCR-06-1868","article-title":"Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019111912154776300_B17","doi-asserted-by":"crossref","article-title":"B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence.","author":"Routh","DOI":"10.1016\/j.juro.2008.01.056"},{"issue":"3","key":"2019111912154776300_B18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.","volume":"15","author":"Gao","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2019111912154776300_B19","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer.","volume":"13","author":"Nomi","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111912154776300_B20","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2019111912154776300_B21","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111912154776300_B22","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111912154776300_B23","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2019111912154776300_B24","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2019111912154776300_B25","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111912154776300_B26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2019111912154776300_B27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma.","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111912154776300_B28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/leu.2008.272","article-title":"PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients.","volume":"23","author":"Kozako","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111912154776300_B29","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111912154776300_B30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/path.4699","article-title":"CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia\/lymphoma with poor prognosis.","volume":"238","author":"Yoshida","year":"2016","journal-title":"J Pathol"},{"issue":"7","key":"2019111912154776300_B31","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","article-title":"B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.","volume":"169","author":"Mazanet","year":"2002","journal-title":"J Immunol"},{"issue":"4","key":"2019111912154776300_B32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance.","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"2019111912154776300_B33","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.","author":"Kwon","journal-title":"Histopathology"},{"issue":"4","key":"2019111912154776300_B34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders.","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"2019111912154776300_B35","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","article-title":"Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.","volume":"49","author":"Droeser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"127","key":"2019111912154776300_B36","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"issue":"8","key":"2019111912154776300_B37","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"issue":"200","key":"2019111912154776300_B38","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"issue":"12","key":"2019111912154776300_B39","doi-asserted-by":"crossref","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","article-title":"Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"19","key":"2019111912154776300_B40","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111912154776300_B41","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","article-title":"PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111912154776300_B42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111912154776300_B43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","article-title":"A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.","volume":"16","author":"Wahlin","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111912154776300_B44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review.","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/10\/1374\/1395151\/1374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/10\/1374\/1395151\/1374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T19:19:49Z","timestamp":1574191189000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/10\/1374\/35318\/PDL1-expression-on-neoplastic-or-stromal-cells-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-02-698936","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}